Semaglutide Linked to Reduced Alzheimer’s Disease Risk in Type 2 Diabetics
A study analyzing nearly 1.7 million patients with type 2 diabetes found that semaglutide significantly reduces Alzheimer’s disease and vascular dementia risk compared to other diabetes medications. Patients taking semaglutide had a 46% lower risk of developing Alzheimer’s disease, including vascular dementia, than those on insulin or metformin. The study suggests potential neuroprotective benefits for … Read more